Mad Hedge Technology Letter
September 7, 2022
Fiat Lux
Featured Trade:
(JUST A BLIP)
(ISO), (TSLA)
Tag Archive for: (ISO)
Brushing your teeth will be the least of tech’s worries as California’s power grid operator declared a stage 3 energy emergency alert.
Rotating power outage warnings were “highly likely” as a bone-crushing heat wave descended on the Golden State and the American West stressing the electricity grid to the extreme limit.
I’ve never tried brushing my teeth in the dark, but I imagine it’s not easy.
Toothpaste dripping all over my pajamas is not what I imagine when I think about living the California dream.
Luckily, I installed my luxury solar panel system on my roof that fully charges my 2 Teslas in the garage for free.
Tough obstacles call for smart solutions.
For others, DEFCON 5 is front and center.
California Independent System Operator (ISO) tweeted to customers advising them to “please reduce your energy use.”
Some 67,000 Californians were without power Monday evening.
Tech CEOs are taking notice as Silicon Valley, although blemished from its golden and most lucrative years, is still a massive hub of tech entrepreneurship, innovation, and investment.
There are about half a million tech jobs in the greater San Francisco Bay Area, and it doesn’t take a genius to understand they need the light on to work.
Talking to tech CEOs, they are perplexed.
Various CFOs and CTOs are having private conversations about buying backup power generators to kick in if power fails at the office.
There are also newer conversations about investing in office space outside the San Francisco tech region, and naturally, those locations gravitate towards cooler regions with better access to water sources.
Tech CEOs that now mandate 100% remote work can sit back and relax knowing that even if a few get taken out, most of the staff will be online from somewhere somehow and someway.
The staff at Mad Hedge Fund Trader are employed over 13 different time zones around the world and boast a similar setup to mine, which are roof solar panels powering a fleet of Teslas. Throw in a satellite signal for broadband internet.
I don’t believe energy prices will factor into the tech earnings this upcoming quarter as electricity prices in California soared to their highest since California's electric grid operator imposed rotating outages in August 2020.
The last time the ISO ordered utilities to shed power was for two days in August 2020 when outages affecting about 800,000 homes and businesses lasted anywhere from 15 minutes to about two-1/2 hours.
At worst, there might be a mini footnote writing down a small sum for electricity bills. Remember that these behemoths earn billions upon billions of annual revenues.
At the individual level, however, convincing the incremental tech worker to move to Silicon Valley has been tough, this just made it infinitely harder.
In the bigger scheme of things, naturally, this is just a blip in the process of going green and for tech taking a larger part of the economic opportunities.
By 2035, the State of California will ban the new sale of gas-powered vehicles giving way to a beautiful renaissance of EVs helmed by the CEO of Tesla Elon Musk.
It’s likely that half of California residents will be driving a Tesla by 2035 and these energy breakages only speed up the process of adoption.
These same tech CFOs are already talking about outfitting their offices with an array of the best solar panels that money can buy as well as recommending that employees choose a more efficient fuel-consuming automobile to drive.
Adapt or stagnate.
Mad Hedge Bitcoin Letter
October 14, 2021
Fiat Lux
Featured Trade:
(WHAT’S NEW IN BIOTECH)
(CGTX), (BIIB), (LLY), (ABBV), (NVS), (TAK), (PYXS), (PFE),
(AZN), (GILD), (GSK), (IMGN), (ISO), (TMO), (BIO)
As the biotechnology world is ever-evolving, with several companies going public every few months, let me share some of the most promising names that recently emerged.
The first is Cognition Therapeutics (CGTX), a company working on treatments for Alzheimer’s disease and macular degeneration.
Its most promising candidate is an Alzheimer’s treatment called CT1812, which is currently under Phase 2 trials. Looking at the timeline, CGTX expects to release topline data by 2023.
With the expected growth of the aging population, focusing on treating various forms of Alzheimer’s is a promising direction for Cognition Therapeutics.
In fact, the global market for this neurodegenerative disease is projected to grow from $2.9 billion in 2018 to a whopping $10.5 billion by 2025.
So far, the major competitors of Cognition Therapeutics in this area include Biogen (BIIB), Eli Lilly (LLY), AbbVie (ABBV), Novartis (NVS), and Takeda (TAK).
The second promising biotech company is Pyxis Oncology (PYXS), which is a spinoff from Pfizer (PFE).
Pyxis is focused on developing next-generation treatments targeting difficult-to-treat types of cancer.
Basically, the company’s goal is to create therapies that can directly kill tumor cells. It also wants to get rid of the underlying problems that lead to the uncontrollable spread of tumors and the weakening of the immune system.
To do this, Pyxis has come up with novel antibody drug conjugate (ACT) candidates and other monoclonal antibody (mAb) pipelines.
Its lead candidate is called ADC PYX-201, a potential treatment for non-small cell lung cancer and breast cancer.
The goal of ADC PYX-201 is to target actively multiplying tumors while boosting the immune response of the patient’s body. Pyxis plans to submit it as a non-small cell lung cancer treatment candidate by mid-2022.
If approved, then ADC PYX-201 will be under patent protection until 2037.
This holds great potential for Pyxis’ cashflow, as the market for non-small cell lung cancer worldwide is anticipated to rise from $6.2 billion in 2016 to over $12 billion by 2025.
With this potential of ADC treatments, Pyxis can expect competition from the likes of AstraZeneca (AZN), Gilead Sciences (GILD), GlaxoSmithKline (GSK), and ImmunoGen (IMGN).
The last name on today’s list is IsoPlexis Corporation (ISO).
This company is the first to focus on dynamic proteomics and single-cell biology in an effort to develop “walk-away automation” products that aid in shortening the therapeutic development timelines by acquiring “multiplexed proteomics with very low sample volumes that reflect in vivo biology to clarify lead candidates.”
In layman’s terms, IsoPlexis is working on a technology that aims to identify every protein in the body to speed up the development of new therapies for rare diseases.
This is a lucrative business, with IsoPlexis targeting at least $34 billion in the total addressable market.
Considering that IsoPlexis is a pioneer in this field, it is possible for it to gain the lion’s share of the segment and position itself as an undisputed leader for years.
More importantly, IsoPlexis can use its patented technology, “Proteomic Barcoded,” to expand the use cases to cover other lucrative markets.
For example, IsoPlexis can apply its technology to cancer immunology and targeted oncology by predicting the progression of cancer cells in the body.
Adding cell therapies to the company’s pipeline is also a very realistic possibility since its technology can be utilized to create CAR-T cell therapies as well.
In fact, IsoPlexis’ approach is already being used in developing treatments for leukemia and melanoma.
Another profitable avenue for IsoPlexis’ technology is the vaccines sector.
Since the development of vaccines requires profiling the responses of the respiratory and immune systems, the company’s data would accelerate the entire process.
So far, the major rivals of IsoPlexis in this space include Thermo Fisher Scientific (TMO) and Bio Rad Laboratories (BIO).
While all these biotech companies offer promising products and technologies, they’re all still in the early stages of development.
This makes them high-risk investments and are likely suitable for those who are willing to invest in the long term.
For those who want to see movement faster and sooner, it might be best to watch these stocks from the sidelines.
